ReviewFrontiers in gastroenterology (Lausanne, Switzerland)2026
Recent advances, comparative performance, and data requirements of artificial intelligence-assisted technologies for the diagnosis of gastric cancer.
Review in Frontiers in gastroenterology (Lausanne, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Early diagnosis of gastric cancer is critical for improving prognosis and increasing the 5-year survival rate. However, gastroscopy and pathological examination are invasive, resource-dependent, and associated with low adherence, while conventional serological and imaging screening methods have limited sensitivity for early lesions. In recent years, artificial intelligence (AI), especially deep learning, has improved the efficiency and accuracy of real-time endoscopic detection, digital pathological recognition, non-contrast CT-based opportunistic screening, and multimodal diagnostic decision support. This review summarizes recent advances in AI-assisted technologies for gastric cancer diagnosis and, in response to the need for a clearer methodological and quantitative framework, compares representative models according to data modality, model architecture, dataset size, validation strategy, and reported diagnostic performance, including AUC, accuracy, sensitivity, specificity, precision/positive predictive value (PPV), and F1 score when available. We further discuss how data size, modality diversity, annotation granularity, class imbalance, and missing modalities influence model performance in real-world multicenter settings. Finally, we propose a structured multimodal AI-clinical decision support system (AI-CDSS) framework integrating CT imaging, endoscopic images and videos, whole-slide pathological images, serological indicators, molecular biomarkers, and clinical reports. Although AI-assisted diagnosis has shown considerable promise, clinical translation still requires prospective multicenter validation, standardized reporting of performance metrics, interpretable model outputs, privacy-preserving data governance, and regulatory-compliant deployment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.